Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science [PDF]
Clinical and Translational ScienceIbrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal ...
Adelynne H. Walley +3 more
doaj +5 more sources
Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials [PDF]
HeliyonBackground: This study aims to evaluate the efficacy and safety associated with ibrexafungerp in the treatment of vulvovaginal candidiasis infection patients.
Fei Lin
exaly +6 more sources
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Journal of Investigative Medicine High Impact Case Reports, 2022 Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited.
Robert Orenstein, Leah Grant
exaly +4 more sources
Journal of Fungi (Basel, Switzerland), 2022 Invasive fungal diseases (IFD) remain a major cause of morbidity and mortality in hematological patients, especially those undergoing hematopoietic stem cell transplantation (HSCT).
Vidmantas Petraitis, Andrius Žučenka
exaly +5 more sources
Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
Journal of Fungi (Basel, Switzerland), 2022 Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies.
Ana Alastruey-Izquierdo +2 more
exaly +9 more sources
Candida glabrata Prosthetic Joint Infection Managed with Ibrexafungerp [PDF]
Journal of FungiWe report a case of a triazole and echinocandin-resistant C. glabrata right shoulder prosthetic joint infection in a 60-year-old woman. The patient underwent surgery and received the novel triterpenoid antifungal agent ibrexafungerp.
Ella Nadarevic +2 more
doaj +4 more sources
Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor [PDF]
Journal of Fungi (Basel, Switzerland), 2021 Ibrexafungerp (formerly SCY-078 or MK-3118) is a first-in-class triterpenoid antifungal or “fungerp” that inhibits biosynthesis of β-(1,3)-D-glucan in the fungal cell wall, a mechanism of action similar to that of echinocandins.
Nelesh Govender, Sabelle Jallow
exaly +5 more sources
Drug Design, Development and Therapy, 2023 Nancy A Phillips, Maria Rocktashel, Lena Merjanian Department Obstetrics, Gynecology & Reproductive Sciences, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USACorrespondence: Nancy A Phillips, Department Obstetrics, Gynecology ...
Phillips NA, Rocktashel M, Merjanian L
exaly +5 more sources
Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata [PDF]
Frontiers in Cellular and Infection Microbiology, 2021 Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients.
Thomas McCormick +2 more
exaly +5 more sources
Real-World Ibrexafungerp Use Patterns Among Patients with Commercial Health Insurance, United States, 2021–2023 [PDF]
Drugs - Real World OutcomesBackground Vulvovaginal candidiasis (VVC) is a common gynecological complaint. Ibrexafungerp (brand name: Brexafemme®) is a new, first-in-class oral antifungal medication approved as a 1-day treatment for VVC and as a monthly treatment to reduce ...
Kaitlin Benedict +2 more
doaj +2 more sources